PT  - JOURNAL ARTICLE
AU  - Martín-Varillas, José Luis
AU  - Sanchez-Bilbao, Lara
AU  - Calvo-Río, Vanesa
AU  - Adán, Alfredo
AU  - Hernanz, Inés
AU  - Gallego-Flores, Adela
AU  - Beltran-Catalan, Emma
AU  - Castro-Oreiro, Sonia
AU  - Fanlo, Patricia
AU  - Garcia Martos, Alvaro
AU  - Torre, Ignacio
AU  - Cordero-Coma, Miguel
AU  - De Dios, Juan Ramon
AU  - García-Aparicio, Ángel
AU  - Hernández-Garfella, Marisa
AU  - Sánchez-Andrade, Amalia
AU  - García-Valle, Andrea
AU  - Maiz, Olga
AU  - Miguélez, Roberto
AU  - Rodríguez-Montero, Sergio
AU  - Urruticoechea, Ana
AU  - Veroz, Raúl
AU  - Conesa, Arantxa
AU  - Fernández-Carballido, Cristina
AU  - Jovaní, Vega
AU  - Mondejar, Jose J
AU  - Martínez González, Olga
AU  - Moya Alvarado, Patricia
AU  - Romero-Yuste, Susana
AU  - Rubio-Muñoz, Paula
AU  - Peña-Sainz-Pardo, Eva
AU  - Garijo-Bufort, Marta
AU  - Demetrio-Pablo, Rosalía
AU  - Hernández, José L
AU  - Blanco, Ricardo
TI  - Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients
AID  - 10.1136/rmdopen-2022-002693
DP  - 2022 Dec 01
TA  - RMD Open
PG  - e002693
VI  - 8
IP  - 2
4099  - http://rmdopen.bmj.com/content/8/2/e002693.short
4100  - http://rmdopen.bmj.com/content/8/2/e002693.full
SO  - RMD Open2022 Dec 01; 8
AB  - Objectives To evaluate effectiveness and safety of certolizumab pegol (CZP) in uveitis due to immune-mediated inflammatory diseases (IMID).Methods Multicentre study of CZP-treated patients with IMID uveitis refractory to conventional immunosuppressant. Effectiveness was assessed through the following ocular parameters: best-corrected visual acuity, anterior chamber cells, vitritis, macular thickness and retinal vasculitis. These variables were compared between the baseline, and first week, first, third, sixth months, first and second year.Results We studied 80 (33 men/47 women) patients (111 affected eyes) with a mean age of 41.6±11.7 years. The IMID included were: spondyloarthritis (n=43), Behçet’s disease (n=10), psoriatic arthritis (n=8), Crohn’s disease (n=4), sarcoidosis (n=2), juvenile idiopathic arthritis (n=1), reactive arthritis (n=1), rheumatoid arthritis (n=1), relapsing polychondritis (n=1),Conclusions CZP seems to be effective and safe in uveitis related to different IMID, even in patients refractory to previous biological drugs.No data are available.